{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:33:31Z","timestamp":1787668411311,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.disamonth.2025.101970","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:21:11Z","timestamp":1750432871000},"page":"101970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A comprehensive review of the treatment options in myasthenia gravis"],"prefix":"10.1016","volume":"71","author":[{"given":"Alexander J","family":"Randall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2025.101970_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116428","article-title":"Myasthenia gravis: historical achievements and the \u201cgolden age\u201d of clinical trials","volume":"406","author":"Nguyen-Cao","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.disamonth.2025.101970_bib0002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/brain\/23.2.277","article-title":"Myasthenia gravis","volume":"23","author":"CAMPBELL","year":"1900","journal-title":"Brain"},{"key":"10.1016\/j.disamonth.2025.101970_bib0003","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00000658-193910000-00005","article-title":"Myasthenia gravis and tumors of the Thymic region report of a case in which the tumor was removed","volume":"110","author":"BLALOCK","year":"1939","journal-title":"Ann Surg"},{"key":"10.1016\/j.disamonth.2025.101970_bib0004","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis With physostigmine","volume":"223","author":"Walker","year":"1934","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2025.101970_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/003693306000501001","article-title":"Myasthenia gravis: a new hypothesis","volume":"5","author":"Simpson","year":"1960","journal-title":"Scott Med J"},{"key":"10.1016\/j.disamonth.2025.101970_bib0006","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"MANN","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0007","first-page":"293","article-title":"Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors","volume":"182","author":"Fambrough","year":"1973","journal-title":"Science (1979)"},{"key":"10.1016\/j.disamonth.2025.101970_bib0008","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High-dose intravenous Gammaglobulin for myasthenia gravis","volume":"323","author":"Gajdos","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2025.101970_bib0009","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archinte.1986.00360190143020","article-title":"High-dose intravenous immunoglobulin in the management of myasthenia gravis","volume":"146","author":"Arsura","year":"1986","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.disamonth.2025.101970_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006986.pub3","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","volume":"2014","author":"Mehndiratta","year":"2014","journal-title":"Cochrane Database System Rev"},{"key":"10.1016\/j.disamonth.2025.101970_bib0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/jnnp.43.7.644","article-title":"Controversies about the treatment of myasthenia gravis","volume":"43","author":"Rowland","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.disamonth.2025.101970_bib0012","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.disamonth.2025.101970_bib0013","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.nmd.2022.09.002","article-title":"The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study","volume":"32","author":"Remijn-Nelissen","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.disamonth.2025.101970_bib0014","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of Myasthenia Gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.disamonth.2025.101970_bib0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1540-8167.2007.00938.x","article-title":"Treatment of Pyridostigmine-induced AV block with HYOSCYAMINE in a patient with myasthenia gravis","volume":"19","author":"Gehi","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0016","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0017","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12028-021-01259-4","article-title":"Acetylcholinesterase inhibitors in myasthenic crisis: a systematic review of observational studies","volume":"35","author":"Prado","year":"2021","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.disamonth.2025.101970_bib0018","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/08820538.2023.2194984","article-title":"The icepack test in the diagnosis of myasthenia gravis with ocular features: a systematic review of diagnostic accuracy, technique, and economic utility","volume":"38","author":"Proudman","year":"2023","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0019","doi-asserted-by":"crossref","unstructured":"Warmolts, J. R. & Engel, W. K. Benefit from Alternate-Day Prednisone in Myasthenia Gravis. New England J Med 286, 17\u201320 (1972).","DOI":"10.1056\/NEJM197201062860104"},{"key":"10.1016\/j.disamonth.2025.101970_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0021","doi-asserted-by":"crossref","unstructured":"Farmakidis, C., Pasnoor, M., Dimachkie, M. M. & Barohn, R. J. Treatment of myasthenia gravis. doi:10.1016\/j.ncl.2018.01.011.","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"10.1016\/j.disamonth.2025.101970_bib0022","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"268","author":"Lotan","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0023","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0024","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.disamonth.2025.101970_bib0025","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1001\/jama.2023.18862","article-title":"Prophylaxis Against Pneumocystis Pneumonia","volume":"330","author":"Caplan","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.disamonth.2025.101970_bib0026","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0027","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ene.14547","article-title":"Chronic immunoglobulin maintenance therapy in myasthenia gravis","volume":"28","author":"Alcantara","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0028","doi-asserted-by":"crossref","unstructured":"Bril, V. et al. Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis. 100, 671\u2013682 (2023).","DOI":"10.1212\/WNL.0000000000201501"},{"key":"10.1016\/j.disamonth.2025.101970_bib0029","article-title":"Plasma exchange for myasthenia gravis","volume":"2002","author":"Gajdos","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.disamonth.2025.101970_bib0030","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0031","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mus.23626","article-title":"Safety of plasma exchange therapy in patients with myasthenia gravis","volume":"47","author":"Ebadi","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.disamonth.2025.101970_bib0032","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0033","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0034","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/WNL.38.2.258","article-title":"Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis","volume":"38","author":"Hohlfeld","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.36.1.35","article-title":"Azathioprine toxicity in neuromuscular disease","volume":"36","author":"Kissel","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0036","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.disamonth.2025.101970_bib0037","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/0003-4819-154-12-201106210-00009","article-title":"Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review","volume":"154","author":"Booth","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.disamonth.2025.101970_bib0038","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.mcna.2012.05.001","article-title":"Immunotherapies in Neurologic Disorders","volume":"96","author":"Graves","year":"2012","journal-title":"Med Clinic North Am"},{"key":"10.1016\/j.disamonth.2025.101970_bib0039","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0041","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0042","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0043","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0046","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2025.101970_bib0047","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"TINDALL","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.disamonth.2025.101970_bib0048","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of Myasthenia gravis\u2013a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0049","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u2018rebooting\u2019 with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.disamonth.2025.101970_bib0051","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.31.1.32","article-title":"Stable remissions in myasthenia gravis","volume":"31","author":"Perez","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101970_bib0052","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.disamonth.2025.101970_bib0053","first-page":"V3","article-title":"Cyclophosphamide","volume":"1-9","author":"Stork","year":"2023","journal-title":"Encyclopedia Toxicol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0054","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.disamonth.2025.101970_bib0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis the Rinomax randomized clinical trial supplemental content","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0056","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.disamonth.2025.101970_bib0057","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","article-title":"PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents","volume":"6","author":"Kanth","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.disamonth.2025.101970_bib0058","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clinic Investigat"},{"key":"10.1016\/j.disamonth.2025.101970_bib0059","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.disamonth.2025.101970_bib0061","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0062","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0063","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0064","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.disamonth.2025.101970_bib0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalized myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0066","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New Eng J Med"},{"key":"10.1016\/j.disamonth.2025.101970_bib0067","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpedsurg.2005.10.006","article-title":"Long-term follow-up after thymectomy for myasthenia gravis: thoracoscopic vs open","volume":"41","author":"Wagner","year":"2006","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.disamonth.2025.101970_bib0068","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/jcm13041136","article-title":"Transient neonatal myasthenia gravis as a common complication of a rare disease: a systematic review","volume":"13","author":"Lindroos","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2025.101970_bib0069","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/jcm12010130","article-title":"Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series","volume":"12","author":"Marco","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2025.101970_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin","year":"2024","journal-title":"Frontiers Neurol"},{"key":"10.1016\/j.disamonth.2025.101970_bib0071","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502925001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502925001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T13:10:03Z","timestamp":1754572203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502925001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0011502925001245"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.101970","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of the treatment options in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.101970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101970"}}